enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · IEX Real-Time Price · USD
5.28
-0.18 (-3.30%)
At close: Mar 27, 2024, 4:00 PM
5.44
+0.16 (3.03%)
After-hours: Mar 27, 2024, 4:55 PM EDT
Company Description
enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases.
The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease.
Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg.
The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.
enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
enVVeno Medical Corporation
Country | United States |
Founded | 1987 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 31 |
CEO | Robert A. Berman |
Contact Details
Address: 70 Doppler Irvine, California 92618 United States | |
Phone | 949-261-2900 |
Website | envveno.com |
Stock Details
Ticker Symbol | NVNO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001661053 |
CUSIP Number | 29415J106 |
ISIN Number | US29415J1060 |
Employer ID | 33-0936180 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Robert A. Berman | Chief Executive Officer and Director |
Craig Thomas Glynn | Chief Financial Officer, Treasurer and Secretary |
Dr. Hamed Alavi Ph.D. | Senior Vice President and Chief Technology Officer |
Dr. Marc H. Glickman M.D. | Senior Vice President and Chief Medical Officer |
Warren Hancock | Co-founder |
Dr. Benedict Broennimann M.D. | Chief Medical Officer of Outside of United States |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 6, 2024 | 8-K | Current Report |
Feb 29, 2024 | 10-K | Annual Report |
Feb 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Dec 7, 2023 | 8-K | Current Report |
Nov 16, 2023 | 8-K | Current Report |
Nov 3, 2023 | EFFECT | Notice of Effectiveness |
Nov 3, 2023 | DEF 14A | Other definitive proxy statements |
Oct 26, 2023 | S-3 | Registration statement under Securities Act of 1933 |